Navigation Links
Trubion Pharmaceuticals Announces Presentation of Positive TRU-015 and SBI-087 Data at the 2008 Annual European Congress of Rheumatology Meeting
Date:6/16/2008

at the time of this assessment. Re-treatment with TRU-015 did not result in an increase in any adverse events compared with the initial infusion, and the re-treatment infusions were well-tolerated. B-cell depletion and recovery following re-treatment with TRU-015 was comparable to that seen after initial treatment. Ongoing patient evaluations showed maintenance of ACR responses following administration of a single dose of TRU-015 at six-month intervals.

Trubion announced in May that Wyeth had commenced patient dosing in the next Phase 2b clinical trial of TRU-015 in patients with RA. The randomized, parallel, double-blind, placebo-controlled, dose-regimen-finding study will evaluate the safety and efficacy of two dosing regimens. Treatment will be administered to approximately 216 patients with active, seropositive RA on a background of methotrexate. The primary outcome measurement for the TRU-015 Phase 2b study will be the ACR 50 response measured at 24 weeks. Secondary outcome measurements will be ACR 20 and Disease Activity Score-28 responses.

SBI-087 Demonstrates Favorable in Vivo B-Cell Depletion and Pharmacokinetic Profiles (THU0171)

SBI-087 is a humanized SMIP drug candidate that is directed against the CD20 antigen. The objective of the preclinical study conducted by Wyeth was to evaluate the pharmacokinetics and pharmacodynamics of SBI-087 following a single intravenous dose. Administration of SBI-087 resulted in dose-dependent B-lymphocyte depletion in peripheral blood and lymphoid tissues that was more profound and sustained in SBI-087-treated groups compared with rituximab.

In April, Trubion announced that Wyeth initiated a Phase 1 SBI-087 dose escalation clinical trial that is designed to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of a single dose of SBI-087 in patients with RA. This Phase I trial is designed to enroll patients who meet the criteria for RA with Functional Class I, II or III, and
'/>"/>

SOURCE Trubion Pharmaceuticals Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Trubion Announces Presentation of Positive TRU-016 Data at ASCO
2. Trubion Announces Initiation of Phase 2b Study of TRU-015 for the Treatment of Rheumatoid Arthritis
3. Trubion Announces Initiation of Phase 1 Study of SBI-087 for the Treatment of Rheumatoid Arthritis
4. Trubion Initiates Phase 1/2 Study of TRU-016 in CLL, Announces Next-Generation Product Candidate for RA and Provides Product Pipeline Update
5. Trubion Announces Initiation of Phase I/II Clinical Trial of TRU-015 for the Treatment of B-Cell Non-Hodgkins Lymphoma
6. Trubion Pharmaceuticals Announces Presentation of Positive Data From Phase IIb and Re-treatment Studies With TRU-015 in Patients With Rheumatoid Arthritis
7. Trubion Announces Preliminary Analysis of Phase IIb Results With TRU-015 in Rheumatoid Arthritis
8. Quatrx Pharmaceuticals Presents Results From Ophena(TM) (Ospemifene Tablets) Phase 3 Study Related to Treatment of Symptoms of Vulvovaginal Atrophy
9. Sunesis Pharmaceuticals Presents Data from Clinical Trials of Voreloxin (formerly SNS-595) in Patients with Acute Myeloid Leukemia at the 13th Congress of the European Hematology Association
10. European Enrollment Begins in Pivotal Phase 3 Trial of Novel Combination Medicine Developed by Cogentus Pharmaceuticals
11. Vion Pharmaceuticals Announces Presentation of Data of Cloretazine(R) (VNP40101M) in Elderly Patients with High-Risk Myelodysplastic Syndromes at the EHA Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/3/2015)... , June 3, 2015  Lightlake Therapeutics ... addiction treatments based on its expertise in opioid ... Lightlake,s partner for treating opioid overdose with intranasal ... New Drug Application (NDA) to the United States ... spray formulation of naloxone, a drug intended to ...
(Date:6/3/2015)... 3, 2015  Halozyme Therapeutics, Inc. (NASDAQ: ... license agreement with AbbVie (NYSE: ABBV ) to ... with Halozyme,s ENHANZE ™ platform. ... will receive an initial $23 million payment, followed ... each of up to nine collaboration targets. These ...
(Date:6/3/2015)... 2015  VA North Texas Health Care System ... vBloc, a technology-based, scientifically advanced weight loss therapy.  ... called the Maestro® Rechargeable System that intermittently blocks ... involving food intake and processing between the brain ... customizable to meet the needs of a patient,s ...
Breaking Medicine Technology:Lightlake Therapeutics Inc. Announces Adapt Pharma Limited Commences Rolling NDA Submission To The FDA For Intranasal Naloxone 2Lightlake Therapeutics Inc. Announces Adapt Pharma Limited Commences Rolling NDA Submission To The FDA For Intranasal Naloxone 3Halozyme Enters Into Global Collaboration and Licensing Agreement With AbbVie 2Halozyme Enters Into Global Collaboration and Licensing Agreement With AbbVie 3VA North Texas First VA in the Country to Perform vBloc Implant, a Cutting-Edge Weight Loss Therapy 2VA North Texas First VA in the Country to Perform vBloc Implant, a Cutting-Edge Weight Loss Therapy 3
(Date:6/3/2015)... (PRWEB) June 03, 2015 The Canton ... transforms businesses with technology, announced today that Tim Dodge ... Mr. Dodge joins The Canton Group as ... of successful customer engagements. , Tim is a tech ... for a variety of technology companies. Before joining The ...
(Date:6/3/2015)... Seattle, WA (PRWEB) June 03, 2015 On ... for the majority of genetic drug sensitivity (pharmacogenetic) testing that ... expected to impact as many as 19 million of the ... special risk of costly and life-threatening adverse drug events.(1) Sadly, ... save Medicare millions. , Precision Medicine, the use of an ...
(Date:6/3/2015)... June 03, 2015 Horizon Blue Cross Blue ... Magazine as one of the nation’s top employers for diverse ... 6 among its national list of Best Places for Diverse ... the No. 1 Regional Company. This is the sixth ... MBA Magazine for its diverse workplace policies and programs. , ...
(Date:6/3/2015)... (PRWEB) June 03, 2015 A group ... be honored with a Global Inspire Award at DIA’s ... the organization’s outstanding volunteers for their leadership, level of ... , The recipients of the Author(s) of ... of authors whose article has made a significant impact ...
(Date:6/3/2015)... Visual BI Solutions, a leader in ... launch of the second release of its successful ... Studio. The Design Studio EXtension suite allows customers ... into their dashboarding projects. , With the second ... adding key components for customers that are looking ...
Breaking Medicine News(10 mins):Health News:The Canton Group Appoints Tim Dodge as Chief Marketing Officer 2Health News:Medicare Limiting Coverage Benefit for Drug Sensitivity Testing on June 22, 2015 2Health News:Medicare Limiting Coverage Benefit for Drug Sensitivity Testing on June 22, 2015 3Health News:Medicare Limiting Coverage Benefit for Drug Sensitivity Testing on June 22, 2015 4Health News:Medicare Limiting Coverage Benefit for Drug Sensitivity Testing on June 22, 2015 5Health News:Medicare Limiting Coverage Benefit for Drug Sensitivity Testing on June 22, 2015 6Health News:Medicare Limiting Coverage Benefit for Drug Sensitivity Testing on June 22, 2015 7Health News:Horizon Blue Cross Blue Shield of New Jersey Named a 2015 Best Place for Diverse Managers and Women to Work by Diversity MBA Magazine 2Health News:Authors Representing TransCelerate BioPharma Inc. to Be Honored with Global Inspire Award at DIA’s 2015 51st Annual Meeting 2Health News:Authors Representing TransCelerate BioPharma Inc. to Be Honored with Global Inspire Award at DIA’s 2015 51st Annual Meeting 3Health News:Authors Representing TransCelerate BioPharma Inc. to Be Honored with Global Inspire Award at DIA’s 2015 51st Annual Meeting 4Health News:Visual BI Launches Second Release for its Design Studio EXtensions (DSX) for SAP® BusinessObjects™ Design Studio 2Health News:Visual BI Launches Second Release for its Design Studio EXtensions (DSX) for SAP® BusinessObjects™ Design Studio 3
... Wednesday evening swayed to the tunes of catchy Bollywood ... awareness// that saw participation of over 10,000 sex workers ... a pair of black trousers, matching shirt and a ... Jalaile" to the delight of the mixed gathering of ...
... with gonorrhea is probably twice as likely to develop bladder ... results in the British Journal of Cancer, lead author David ... the statement based on case studies of around 51,000 American ... men suffering from gonorrhea. Results analyzed showed that ...
... the general public. This was revealed by a research conducted ... ,Among other reasons cited, drug overdose is said to ... ailments, homicides, suicides, cancer, and smoking. This study was conducted ... a researcher and an assistant professor at University of Colorado ...
... grown soy beans may prove to be successful in ... Tulane //University cancer researcher Matthew Burow. ,Burow ... ovarian and breast cancer tumors that are stimulated by ... growth of the tumors by interfering with the tumor’s ...
... emergency medical system in the national capital to help ... and thus reduce fatalities. ,"In collaboration with the ... system in Pune. Delhi will soon have the facility," ... of Indian Origin (AAPI), said Wednesday. ,Under this ...
... acclaimed as the "gold-standard" amongst researchers for scientific studies. ... on the other, has also questioned the worth of ... complementary and alternative medicine (CAM) practices. Majority of CAM ... cure. , ,The question arises as to whether ...
Cached Medicine News:Health News:Gere Jives To Bollywood Songs To Spread AIDS Awareness 2Health News:Indo-American Doctors to Build Emergency Medical System 2Health News:Is Evidence-based Medicine Enough to Support Additional Research in Alternative Medicine? 2
... Direct has been selling replacement ... 1996, and we are extremely ... guarantee. Check out our catalog ... our discount light bulbs specials. ...
... Bulb Direct has been selling ... since 1996, and we are ... satisfaction guarantee. Check out our ... see our discount light bulbs ...
... has been selling replacement bulbs ... and we are extremely proud ... Check out our catalog of ... discount light bulbs specials. ...
With the Symphony family of Pacemakers, Ela presents the most advanced technology on the market. Symphony, lighter than a passport, will take your patients further, offering fast follow-up, using new...
Medicine Products: